Welcome to our dedicated page for Coya Therapeutics news (Ticker: COYA), a resource for investors and traders seeking the latest updates and insights on Coya Therapeutics stock.
Coya Therapeutics, Inc. (NASDAQ: COYA) is a clinical-stage biotechnology company headquartered in Houston, Texas, with news flow centered on its regulatory T cell (Treg)–focused pipeline for neurodegenerative and inflammation-driven diseases. Company updates frequently highlight progress with COYA 302, an investigational proprietary biologic combination of low-dose interleukin-2 (LD IL-2) and CTLA-4 Ig, and COYA 303, an investigational combination of LD IL-2 and a GLP-1 receptor agonist.
Investors following COYA news can expect regular coverage of clinical trial milestones, including the Phase 2 ALSTARS Trial of COYA 302 in amyotrophic lateral sclerosis (ALS). Coya has announced key events such as FDA acceptance of its IND for COYA 302 in ALS, Health Canada’s acceptance of a Clinical Trial Application, initiation and dosing of patients in the ALSTARS Trial, and milestone payments received under its Development and License Agreement with Dr. Reddy’s Laboratories Ltd.
News items also describe regulatory developments for frontotemporal dementia (FTD), including FDA acceptance of an IND for COYA 302 in FTD and results from an investigator-initiated open-label study of low-dose IL-2 and CTLA4-Ig in FTD patients. Additional releases cover preclinical data for COYA 303 in an in vivo model of systemic and neurologic inflammation, corporate financing activities such as an upsized public offering of common stock, and quarterly financial results and corporate updates.
This COYA news page aggregates these disclosures so readers can review clinical, regulatory, scientific, and financing announcements in one place. For those tracking Treg-based approaches to ALS, FTD, Alzheimer’s disease, and related conditions, the news stream provides direct access to Coya’s reported data, trial status updates, and key corporate events over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Coya Therapeutics is advancing its research on Treg therapies to combat Alzheimer's disease (AD), which affects approximately 6 million Americans and is expected to nearly double by 2050. The economic impact of AD is projected to rise from $345 billion to $1 trillion.
The biotechnology firm is preparing to release clinical data on its COYA 301 drug candidate, designed to enhance Treg cells and reduce neuroinflammation. This data is anticipated in mid-May, providing insights from trials involving eight AD patients.
With the global AD treatment market expected to reach $6.3 billion by 2029, Coya positions itself as a leader in Treg-based immunotherapy, attracting interest from major biopharma players like Eli Lilly and Novartis.
Coya Therapeutics (NASDAQ: COYA) has announced results from a proof-of-concept study evaluating COYA 301, a low-dose interleukin-2 (IL-2) therapy for Alzheimer’s Disease (AD). Conducted by Dr. Stanley Appel and Dr. Alireza Faridar at the Houston Methodist Hospital, the study involved eight patients over four months, assessing Treg function and safety. Initial findings suggest potential enhancement of anti-inflammatory responses, crucial for tackling neuroinflammation seen in AD. The study results will be presented at the 2023 Keystone Symposia in Whistler, British Columbia, from May 15-19.
Coya Therapeutics (Nasdaq: COYA) reported its fiscal year 2022 results, highlighting key developments in its drug pipeline. The company achieved positive results in a clinical study of COYA 302 for ALS, showing halted disease progression over 6 months. Coya also entered into a worldwide agreement with Dr. Reddy's Laboratories (NYSE: RDY) to out-license its COYA 301 product candidate.
The company raised approximately $16.4 million from its IPO in January 2023, with cash and equivalents of $5.9 million as of December 31, 2022. However, Coya reported a net loss of $12.2 million for 2022, attributed to increased R&D and administrative expenses.
Coya Therapeutics, Inc. (NASDAQ: COYA) has appointed Dr. Arun Swaminathan as Chief Business Officer. With over 20 years of experience, he will drive business development and partnerships in Coya’s clinical-stage biotechnology pipeline. Notably, during his tenure at Alteogen, he facilitated deals worth $6B and at Actinium Pharmaceuticals, he executed a $452M deal. CEO Howard H. Berman expressed confidence in Swaminathan’s ability to enhance Coya's strategic direction, particularly following recent positive clinical data. Coya focuses on treatments targeting systemic inflammation and neuroinflammation through its Treg-enhancing therapeutic platforms.
Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology firm, announced its participation in the Virtual Investor Summit on March 29, 2023, at 11:00 AM ET. Interested investors are invited to view the webcast here and request one-on-one meetings here. Coya focuses on enhancing Treg functions to combat systemic inflammation through its product pipeline, including biologics and cell therapies.